Updates are available Correction dated 2020-07-09
Click to view Correction: https://doi.org/10.1186/s12882-020-01891-w
-
Authors
Ingrasciotta, Ylenia https://orcid.org/0000-0002-9549-6111
Lacava, Viviana
Marcianò, Ilaria
Giorgianni, Francesco
Tripepi, Giovanni
D’ Arrigo, Graziella
Chinellato, Alessandro
Ugo Tari, Daniele
Santoro, Domenico
Trifirò, Gianluca
-
Funding
Funding for this research was provided by:
Ministero della Salute (RF- 2010-2320172)
- License Information
-
More Information
Article History
Received: 20 September 2018
Accepted: 6 September 2019
First Online: 14 September 2019
Ethics approval and consent to participate
: All procedures performed in this study were in accordance with the Ethical Standards of the Ethics Committee of the Academic Hospital of Messina and of Treviso, according to the current national law [], and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The manuscript does not contain clinical studies, and all patient data were fully anonymized. For this type of study, formal consent is not required.
: Not applicable.
: Gianluca Trifirò declares his participation to advisory boards on biosimilars, organized by Sandoz and Hospira; furthermore, he coordinates a pharmacoepidemiology research team at the University of Messina, which receives research grants for projects that are not related to the topic of the paper. Ylenia Ingrasciotta, Viviana Lacava, Ilaria Marcianò, Francesco Giorgianni, Giovanni Tripepi, Graziella D’Arrigo, Alessandro Chinellato, Daniele Ugo Tari, Domenico Santoro declare that they have no conflicts of interest.
